Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$4.87B |
$53.49
-1.32%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$4.85B |
$30.57
-0.44%
|
|
NOVT
Novanta Inc.
Medical Devices & Biometrics aligning with their focus on medical devices and biometric sensing technologies.
|
$4.84B |
$134.75
+1.18%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.81B |
$80.80
+0.06%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.58B |
$26.32
+1.21%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$4.57B |
$91.08
-1.34%
|
|
TFX
Teleflex Incorporated
Teleflex is a global medical device company designing, manufacturing, and selling single-use medical devices across critical care, surgical, and interventional markets.
|
$4.55B |
$102.94
-1.60%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$4.54B |
$106.88
+1.52%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.48B |
$7.81
-0.64%
|
|
ALHC
Alignment Healthcare, Inc.
Alignment provides Medicare Advantage health insurance via its integrated health plan.
|
$4.46B |
$22.50
-0.02%
|
|
FOLD
Amicus Therapeutics, Inc.
Amicus Therapeutics’s marketed products address rare genetic diseases (Fabry and Pompe) and its pipeline includes a rare-kidney disease program (DMX-200 for FSGS), placing it in Biotech - Rare Diseases.
|
$4.42B |
$14.32
+0.07%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's portfolio includes Pimavanserin (NUPLAZID) and pipeline candidates that are small-molecule therapeutics, with additional small-molecule programs (e.g., ACP-204, ACP-711).
|
$4.38B |
$25.98
-2.05%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$4.37B |
$64.22
-1.83%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.32B |
$44.98
-3.33%
|
|
OSCR
Oscar Health, Inc.
Core product is health insurance plans via ACA marketplace and employer-based offerings, generating premium-based revenue.
|
$4.28B |
$16.53
-5.11%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$4.21B |
$13.40
+1.63%
|
|
NVST
Envista Holdings Corp
Envista directly manufactures dental equipment, including implants and aligners, a core product line.
|
$4.19B |
$25.25
+2.25%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$4.17B |
$54.66
+3.00%
|
|
ADMA
ADMA Biologics, Inc.
ADMA's core offerings are plasma-derived immunology therapeutics (immunoglobulins) used to treat immune deficiencies and related conditions.
|
$4.13B |
$17.32
-1.06%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$4.09B |
$22.14
+0.11%
|
|
INDV
Indivior PLC
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.06B |
$32.53
-1.06%
|
|
CNO
CNO Financial Group, Inc.
Health insurance offerings (including Medicare Supplement) are a core segment.
|
$4.03B |
$41.55
-1.32%
|
|
ICUI
ICU Medical, Inc.
Medical Device Consumables includes disposable items used with infusion therapy (Clave connectors, ChemoLock/ChemoClave CSTDs) and is a core revenue stream.
|
$3.86B |
$156.12
+0.65%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$3.82B |
$68.96
+0.94%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$3.81B |
$33.93
+6.43%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$3.78B |
$193.12
-1.51%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$3.66B |
$34.76
-1.78%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.56B |
$31.68
-0.47%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
GRAL
GRAIL, Inc.
Galleri is a liquid biopsy-based multi-cancer early detection test using cfDNA methylation, the core product.
|
$3.49B |
$96.69
-0.77%
|
|
HAE
Haemonetics Corporation
Medical Device Consumables associated with Haemonetics devices support recurring revenue.
|
$3.48B |
$72.12
-2.54%
|
Showing page 8 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
